Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 2 (2025)

Feasibility of implementing current best clinical practice for people who are using anabolic androgenic steroids within a Swiss primary care practice: a quality assurance study

DOI
https://doi.org/10.57187/s.4225
Cite this as:
Swiss Med Wkly. 2025;155:4225
Published
06.02.2025

Summary

BACKGROUND: The non-medical use of anabolic androgenic steroids for the improvement of aesthetic and sports performance purposes has become a global substance use disorder, particularly among men in recreational sports. Health outcomes among people who are using anabolic androgenic steroids may be detrimental, yet healthcare services for these users are scarce. Therefore, the aim of this project was to conduct a quality assurance study to evaluate the feasibility of providing current best clinical practice for anabolic androgenic steroids users based on the published literature within a primary care practice in Zurich (Switzerland).

METHODS: A primary healthcare practice for current or past anabolic androgenic steroids use was established at the Arud Centre for Addiction Medicine in Zurich providing specialised medical care for this population. The reporting and methodology to evaluate feasibility of this quality assurance study follow a checklist for pilot studies. The primary feasibility outcomes for this study were satisfaction with the services received (customer satisfaction score), as well as loyalty towards the services (net promoter score). These customer metrics have been used successfully in the medical field to measure patient experiences, as well as infer future word-of-mouth advertisement (i.e. return and refer). Furthermore, the objective was to describe patient characteristics and substance use behaviours in a Swiss context. Patients could access these services in Zurich from 1 June 2023 onwards. The recruitment strategy was word-of-mouth advertising among anabolic androgenic steroids users and paper advertisement (i.e. flyers) about the healthcare service. Eligibility criteria were based on legal restrictions regarding doping laws and professional ethical principles of medicine. In an initial visit at the practice, a focused patient history was assessed, and patients received a physical, psychometric, instrumental as well as laboratory examination. Datasets are summarised using descriptive statistics.

RESULTS: Overall, 34 eligible patients were seen over the period from June until December 2023. Excellent results regarding loyalty towards the service (net promoter score: 100; integer) as well as patient satisfaction with the received services (customer satisfaction score: 100%) were achieved. Patients were commonly young professional males (mean: 38.5 years, standard deviation: 8 years), with educational level beyond compulsory schooling. The main motivation for using anabolic androgenic steroids was aesthetic purposes. Acquisition of these substances occurred mostly through non-medical sources. Patterns of anabolic androgenic steroids use were complex with extensive polypharmacy and concomitant illicit substance use. Most patients suffered from side effects with multiple physical as well as mental health complications. Many abnormal findings were found regarding the physical as well as laboratory and instrumental examination, although mostly mild and transient, some possibly severe regarding health outcomes.  

CONCLUSION: With this first quality assurance study, we demonstrate that integration of current best clinical practice for anabolic androgenic steroids users in recreational sports appears to be feasible with high acceptance in a Swiss primary care practice. Furthermore, those patients may engage in high-risk behaviours and a high prevalence of comorbid medical conditions was demonstrated. Anabolic androgenic steroids users likely benefit from integrated medical care provided and coordinated in a primary health care setting. On the basis of the initial study results, these services were continued at a larger scale to further assess as well as mitigate health risks among this user population. Importantly, current doping legislation was demonstrated to be a major limitation to provision of adequate medical care for this user population, thus changes in legislation are crucial to avert this growing public health threat.

References

  1. Kanayama G, Pope HG Jr. History and epidemiology of anabolic androgens in athletes and non-athletes. Mol Cell Endocrinol. 2018 Mar;464:4–13. doi: https://doi.org/10.1016/j.mce.2017.02.039
  2. Ip EJ, Lu DH, Barnett MJ, Tenerowicz MJ, Vo JC, Perry PJ. Psychological and physical impact of anabolic-androgenic steroid dependence. Pharmacotherapy. 2012 Oct;32(10):910–9. doi: https://doi.org/10.1002/j.1875-9114.2012.01123
  3. Bonnecaze AK, O’Connor T, Burns CA. Harm Reduction in Male Patients Actively Using Anabolic Androgenic Steroids (AAS) and Performance-Enhancing Drugs (PEDs): a Review. J Gen Intern Med. 2021 Jul;36(7):2055–64. doi: https://doi.org/10.1007/s11606-021-06751-3
  4. Bonnecaze AK, O’Connor T, Aloi JA. Characteristics and Attitudes of Men Using Anabolic Androgenic Steroids (AAS): A Survey of 2385 Men. Am J Mens Health. 2020;14(6):1557988320966536. doi: https://doi.org/10.1177/1557988320966536
  5. Mullen C, Whalley BJ, Schifano F, Baker JS. Anabolic androgenic steroid abuse in the United Kingdom: an update. Br J Pharmacol. 2020 May;177(10):2180–98. doi: https://doi.org/10.1111/bph.14995
  6. Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol. 2014 May;24(5):383–98. doi: https://doi.org/10.1016/j.annepidem.2014.01.009
  7. Anawalt BD. Diagnosis and Management of Anabolic Androgenic Steroid Use. J Clin Endocrinol Metab. 2019 Jul;104(7):2490–500. doi: https://doi.org/10.1210/jc.2018-01882
  8. Iff S, Butzke I, Quednow B, Gupta R, Imboden C, Claussen M. «Image and performance enhancing drugs» im Freizeitsport. Swiss Medical Forum 2021;21:843-47. Available from: https://pdfs.semanticscholar.org/0a4b/235bbb38cb2885662831e2954db8906f7d01.pdf
  9. Kruijver M, Bruggmann P, Magnolini R. Evidence of use and users of image- and performance-enhancing drugs in sports in Switzerland: a scoping literature review and implications for Swiss drug policy. Swiss Med Wkly. 2023 May;153(5):40080. doi: https://doi.org/10.57187/smw.2023.40080
  10. World Anti-Doping Agency (WADA). Prohibited List 2021. Available from: https://www.wada-ama.org/sites/default/files/resources/files/2021list_en.pdf
  11. Magnolini R, Falcato L, Cremonesi A, Schori D, Bruggmann P. Fake anabolic androgenic steroids on the black market - a systematic review and meta-analysis on qualitative and quantitative analytical results found within the literature. BMC Public Health. 2022 Jul;22(1):1371. doi: https://doi.org/10.1186/s12889-022-13734-4
  12. McBride JA, Carson CC 3rd, Coward RM. The Availability and Acquisition of Illicit Anabolic Androgenic Steroids and Testosterone Preparations on the Internet. Am J Mens Health. 2018 Sep;12(5):1352–7. doi: https://doi.org/10.1177/1557988316648704
  13. Nieschlag E, Vorona E. Doping with anabolic androgenic steroids (AAS): adverse effects on non-reproductive organs and functions. Rev Endocr Metab Disord. 2015 Sep;16(3):199–211. doi: https://doi.org/10.1007/s11154-015-9320-5
  14. Christou MA, Christou PA, Markozannes G, Tsatsoulis A, Mastorakos G, Tigas S. Effects of Anabolic Androgenic Steroids on the Reproductive System of Athletes and Recreational Users: A Systematic Review and Meta-Analysis. Sports Med. 2017 Sep;47(9):1869–83. doi: https://doi.org/10.1007/s40279-017-0709-z
  15. Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Andersen JT, Horwitz H. Mortality Among Users of Anabolic Steroids. JAMA. 2024 Apr;331(14):1229–30. doi: https://doi.org/10.1001/jama.2024.3180
  16. Pope HG Jr, Kanayama G, Athey A, Ryan E, Hudson JI, Baggish A. The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates. Am J Addict. 2014;23(4):371–7. doi: https://doi.org/10.1111/j.1521-0391.2013.12118.x
  17. Skauen JE, Pallesen S, Bjørnebekk A, Chegeni R, Syvertsen A, Petróczi A, et al. Prevalence and correlates of androgen dependence: a meta-analysis, meta-regression analysis and qualitative synthesis. Curr Opin Endocrinol Diabetes Obes. 2023 Dec;30(6):309–23. doi: https://doi.org/10.1097/MED.0000000000000822
  18. Amaral JM, Kimergård A, Deluca P. Prevalence of anabolic steroid users seeking support from physicians: a systematic review and meta-analysis. BMJ Open. 2022 Jul;12(7):e056445. doi: https://doi.org/10.1136/bmjopen-2021-056445
  19. Harvey O, Keen S, Parrish M, van Teijlingen E. Support for people who use Anabolic Androgenic Steroids: A Systematic Scoping Review into what they want and what they access. BMC Public Health. 2019 Jul;19(1):1024. doi: https://doi.org/10.1186/s12889-019-7288-x
  20. Smit DL, de Ronde W. Outpatient clinic for users of anabolic androgenic steroids: an overview. Neth J Med. 2018 May;76(4):167.
  21. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, et al. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol. 2010 Jan;10(1):1. doi: https://doi.org/10.1186/1471-2288-10-1
  22. In J. Introduction of a pilot study. Korean J Anesthesiol. 2017 Dec;70(6):601–5. doi: https://doi.org/10.4097/kjae.2017.70.6.601
  23. Arain M, Campbell MJ, Cooper CL, Lancaster GA. What is a pilot or feasibility study? A review of current practice and editorial policy. BMC Med Res Methodol. 2010 Jul;10(1):67. doi: https://doi.org/10.1186/1471-2288-10-67
  24. Butzke, I., et al., Interdisciplinary and Psychiatric Treatment of Anabolic Androgenic Steroids Users. Praxis (Bern 1994), 2022 Apr;111(6):e339-e344. doi: 10.1024/1661-8157/a003868.
  25. Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014 May;101(5):1271–9. doi: https://doi.org/10.1016/j.fertnstert.2014.02.002
  26. Bond P, Smit DL, de Ronde W. Anabolic-androgenic steroids: how do they work and what are the risks? Front Endocrinol (Lausanne). 2022 Dec;13:1059473. doi: https://doi.org/10.3389/fendo.2022.1059473
  27. Smit DL, Voogel AJ, den Heijer M, de Ronde W. Anabolic Androgenic Steroids Induce Reversible Left Ventricular Hypertrophy and Cardiac Dysfunction. Echocardiography Results of the HAARLEM Study. Front Reprod Health. 2021 Sep;3:732318. doi: https://doi.org/10.3389/frph.2021.732318
  28. de Ronde W, Smit DL. Anabolic androgenic steroid abuse in young males. Endocr Connect. 2020 Apr;9(4):R102–11. doi: https://doi.org/10.1530/EC-19-0557
  29. Camilleri E, Smit DL, van Rein N, Le Cessie S, de Hon O, den Heijer M, et al. Coagulation profiles during and after anabolic androgenic steroid use: data from the HAARLEM study. Res Pract Thromb Haemost. 2023 Oct;7(7):102215. doi: https://doi.org/10.1016/j.rpth.2023.102215
  30. Smit DL, Buijs MM, de Hon O, den Heijer M, de Ronde W. Positive and negative side effects of androgen abuse. The HAARLEM study: A one-year prospective cohort study in 100 men. Scand J Med Sci Sports. 2021 Feb;31(2):427–38. doi: https://doi.org/10.1111/sms.13843
  31. Smit DL, Buijs MM, de Hon O, den Heijer M, de Ronde W. Disruption and recovery of testicular function during and after androgen abuse: the HAARLEM study. Hum Reprod. 2021 Mar;36(4):880–90. doi: https://doi.org/10.1093/humrep/deaa366
  32. Zeeck A, Welter V, Alatas H, Hildebrandt T, Lahmann C, Hartmann A. Muscle Dysmorphic Disorder Inventory (MDDI): validation of a German version with a focus on gender. PLoS One. 2018 Nov;13(11):e0207535. doi: https://doi.org/10.1371/journal.pone.0207535
  33. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG Jr. Issues for DSM-V: clarifying the diagnostic criteria for anabolic-androgenic steroid dependence. Am J Psychiatry. 2009 Jun;166(6):642–5. doi: https://doi.org/10.1176/appi.ajp.2009.08111699
  34. Ip EJ, Barnett MJ, Tenerowicz MJ, Perry PJ. The Anabolic 500 survey: characteristics of male users versus nonusers of anabolic-androgenic steroids for strength training. Pharmacotherapy. 2011 Aug;31(8):757–66. doi: https://doi.org/10.1592/phco.31.8.757
  35. Adams C, Walpola R, Schembri AM, Harrison R. The ultimate question? Evaluating the use of Net Promoter Score in healthcare: A systematic review. Health Expect. 2022 Oct;25(5):2328–39. doi: https://doi.org/10.1111/hex.13577
  36. Koladycz R, Fernandez G, Gray K, Marriott H. The Net Promoter Score (NPS) for Insight Into Client Experiences in Sexual and Reproductive Health Clinics. Glob Health Sci Pract. 2018 Oct;6(3):413–24. doi: https://doi.org/10.9745/GHSP-D-18-00068
  37. Ämmälä AJ, Taimela S. Association Between Patient-Reported Enablement and Customer Satisfaction in 140055 Primary Care Patients After Doctor Appointment. Association Between Patient-Reported Enablement and Customer Satisfaction in 140055 Primary Care Patients After Doctor Appointment. J Patient Exp. 2024 Oct;11:23743735241293631. doi: https://doi.org/10.1177/23743735241293631
  38. Swiss Federal Law. Federal Act on the Promotion of Sport and Exercise. https://www.fedlex.admin.ch/eli/cc/2012/460/en
  39. Anhang 5 zur Standesordnung FMH: Richtlinien für die ärztliche Betreuung von Sporttreibenden. https://www.fmh.ch/ueber-die-fmh/organisation/die-organe-der-fmh/standeskommission.cfm
  40. Wyss W. Betreuung und Behandlung von Patienten mit problematischem Anabolikakonsum und medizinischer Komplikationen ausserhalb des Wettkampfsports. https://zenodo.org/records/13318794
  41. Mulcahey MK, Schiller JR, Hulstyn MJ. Anabolic steroid use in adolescents: identification of those at risk and strategies for prevention. Phys Sportsmed. 2010 Oct;38(3):105–13. doi: https://doi.org/10.3810/psm.2010.10.1815
  42. Hearne E, Atkinson A, Boardley I, McVeigh J, Van Hout MC. ‘Sustaining masculinity’: a scoping review of anabolic androgenic steroid use by older males. Drugs Educ Prev Policy. 2022;31(1):27–53. doi: https://doi.org/10.1080/09687637.2022.2132135
  43. Guerras JM, Hoyos J, de la Fuente L, Román F, Ayerdi O, García-Pérez JN, et al.; The Methysos Project Group. Injection of Anabolic Steroids in Men Who Had Sex with Men in Madrid and Barcelona: Prevalence Correlates and Role as a Risk Factor for Transmitted Infections. Int J Environ Res Public Health. 2021 Aug;18(16):8289. doi: https://doi.org/10.3390/ijerph18168289
  44. Ip EJ, Doroudgar S, Shah-Manek B, Barnett MJ, Tenerowicz MJ, Ortanez M, et al. The CASTRO study: unsafe sexual behaviors and illicit drug use among gay and bisexual men who use anabolic steroids. Am J Addict. 2019 Feb;28(2):101–10. doi: https://doi.org/10.1111/ajad.12865
  45. Amaral JM, Kimergård A, Deluca P. Preventing and treating the adverse health conditions of androgenic-anabolic steroids: an online survey with 883 users in the United Kingdom. Perform Enhanc Health. 2023;11(4):100267. doi: https://doi.org/10.1016/j.peh.2023.100267
  46. Ip EJ, Yadao MA, Shah BM, Lau B. Infectious disease, injection practices, and risky sexual behavior among anabolic steroid users. AIDS Care. 2016;28(3):294–9. doi: https://doi.org/10.1080/09540121.2015.1090539
  47. Fadah K, Gopi G, Lingireddy A, Blumer V, Dewald T, Mentz RJ. Anabolic androgenic steroids and cardiomyopathy: an update. Front Cardiovasc Med. 2023 Jul;10:1214374. doi: https://doi.org/10.3389/fcvm.2023.1214374
  48. Doleeb S, Kratz A, Salter M, Thohan V. Strong muscles, weak heart: testosterone-induced cardiomyopathy. ESC Heart Fail. 2019 Oct;6(5):1000–4. doi: https://doi.org/10.1002/ehf2.12494
  49. Petrovic A, Vukadin S, Sikora R, Bojanic K, Smolic R, Plavec D, et al. Anabolic androgenic steroid-induced liver injury: an update. World J Gastroenterol. 2022 Jul;28(26):3071–80. doi: https://doi.org/10.3748/wjg.v28.i26.3071
  50. Parente Filho SL, Gomes PE, Forte GA, Lima LL, Silva Júnior GB, Meneses GC, et al. Kidney disease associated with androgenic-anabolic steroids and vitamin supplements abuse: be aware! Nefrologia (Engl Ed). 2020;40(1):26–31. doi: https://doi.org/10.1016/j.nefroe.2019.06.005
  51. Ko GJ, Rhee CM, Kalantar-Zadeh K, Joshi S. The Effects of High-Protein Diets on Kidney Health and Longevity. J Am Soc Nephrol. 2020 Aug;31(8):1667–79. doi: https://doi.org/10.1681/ASN.2020010028
  52. Albano GD, Amico F, Cocimano G, Liberto A, Maglietta F, Esposito M, et al. Adverse Effects of Anabolic-Androgenic Steroids: A Literature Review. Healthcare (Basel). 2021 Jan;9(1):97. doi: https://doi.org/10.3390/healthcare9010097
  53. Gupta A, Thorson P, Penmatsa KR, Gupta P. Rhabdomyolysis: revisited. Ulster Med J. 2021 May;90(2):61–9.
  54. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG Jr. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009 Dec;104(12):1966–78. doi: https://doi.org/10.1111/j.1360-0443.2009.02734.x
  55. Grant B, Kean J, Vali N, Campbell J, Maden L, Bijral P, et al. The use of post-cycle therapy is associated with reduced withdrawal symptoms from anabolic-androgenic steroid use: a survey of 470 men. Subst Abuse Treat Prev Policy. 2023 Nov;18(1):66. doi: https://doi.org/10.1186/s13011-023-00573-8
  56. Strauss RH, Yesalis CE. Anabolic steroids in the athlete. Annu Rev Med. 1991;42(1):449–57. doi: https://doi.org/10.1146/annurev.me.42.020191.002313
  57. Thornicroft G, Ahuja S, Barber S, Chisholm D, Collins PY, Docrat S, et al. Integrated care for people with long-term mental and physical health conditions in low-income and middle-income countries. Lancet Psychiatry. 2019 Feb;6(2):174–86. doi: https://doi.org/10.1016/S2215-0366(18)30298-0
  58. Dunn M, Piatkowski T, Whiteside B, Eu B. Exploring the experiences of general practitioners working with patients who use performance and image enhancing drugs. Perform Enhanc Health. 2023 Jun;11(2):100247. doi: https://doi.org/10.1016/j.peh.2023.100247
  59. Piatkowski T, Gibbs N, Dunn M. Beyond the law: exploring the impact of criminalising anabolic–androgenic steroid use on help-seeking and health outcomes in Australia. J Criminol. 2024;57(1):62–82. doi: https://doi.org/10.1177/26338076231209044
  60. Federal Office of Public Health (FOPH). National Strategy on Addiction. Available from: https://www.bag.admin.ch/bag/en/home/strategie-und-politik/nationale-gesundheitsstrategien/strategie-sucht.html

Most read articles by the same author(s)

1 2 3 4 > >>